Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function
出版年份 2012 全文链接
标题
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function
作者
关键词
-
出版物
BLOOD
Volume 119, Issue 9, Pages 2074-2082
出版商
American Society of Hematology
发表日期
2012-01-14
DOI
10.1182/blood-2011-06-364521
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma
- (2011) B. Neuber et al. JOURNAL OF IMMUNOLOGY
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
- (2010) Kihyun Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients
- (2010) Takahiro Ishiguro et al. CANCER SCIENCE
- Antigen-Dependent Internalization Is Related to Rapid Elimination from Plasma of Humanized Anti-HM1.24 Monoclonal Antibody
- (2010) J. Amano et al. DRUG METABOLISM AND DISPOSITION
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy
- (2009) C. Schliemann et al. BLOOD
- Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis
- (2009) Dongqing Cai et al. BMC CANCER
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Optimization of Fc-mediated effector functions of monoclonal antibodies
- (2009) William R Strohl CURRENT OPINION IN BIOTECHNOLOGY
- Lenalidomide in multiple myeloma
- (2009) Bhawna Sirohi et al. Expert Review of Anticancer Therapy
- The impact of Fc engineering on an anti-CD19 antibody: increased Fc receptor affinity enhances B-cell clearing in nonhuman primates
- (2008) J. Zalevsky et al. BLOOD
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
- (2008) Wei Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models
- (2008) Shigeto Kawai et al. CANCER SCIENCE
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells
- (2008) Wei Wang et al. LUNG CANCER
- Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells
- (2008) J. O. Richards et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More